Ketamine One Establishes Medical Advisory Board

Rhea-AI Summary

KetamineOne Capital Limited (KONEF) announced the formation of a new Medical Advisory Board (MAB) to enhance its mental health platform. Chaired by Dr. Mark Kimmins, the MAB includes renowned experts like Dr. Ravi Bains and Dr. Glen Brooks. This strategic move aims to position Ketamine One as a leader in psychedelic-assisted mental health treatments across North America. The company has allocated stock options for the advisors, emphasizing its commitment to developing innovative therapies.

Positive

• Formation of a qualified Medical Advisory Board to guide the development of mental health treatments.
• Expected to enhance Ketamine One's positioning in the psychedelic-assisted therapy market.
• Stock options granted to advisors signify commitment to expertise and innovation in mental health.

Negative

• None.

Led by Dr. Mark Kimmins, the MAB will Help Guide the Development of the Company’s Mental Health Platform

VANCOUVER, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has established a Medical Advisory Board (“MAB”) to help guide the development of Ketamine One’s mental health platform and other aspects of the Company. Chaired by Ketamine One’s Chief Medical Officer, Dr. Mark Kimmins, the MAB’s appointed foundational members also include Dr. Ravi Bains, Dr. Glen Brooks, Dr. Darren Cotterell, Dr. Dennis Filips and Dr. Quang Henderson (the “Medical Advisors”). The Medical Advisors are thought leaders in the fields of psychiatry, psychedelics innovative mental health treatments and veteran affairs, and the Company expects to add other members to the MAB in due course, as appropriate.

Dr. Ravi Bains earned a bachelor’s degree in psychology prior to studying medicine in his home province at the University of Manitoba. He completed a psychiatric residency at Dalhousie University, where he went on to complete a fellowship in Intensive Short Term Dynamic Psychotherapy. After graduating in 2006, Dr. Bains has practiced as an inpatient psychiatrist and a psychotherapist. He has developed a passion for promoting body/mind/spirit health, ‘deprescribing’ and working with trauma. Acutely aware of the limits of conventional psychiatry, Ravi has also developed a strong interest in the potential of psychedelic medicines such as ketamine and psilocybin. He is currently CMO for Wayfound Mental Health Group as well as ATMA Journey Centers.

Dr. Glen Brooks, MD, a board-certified anesthesiologist and pioneer in his field, eight years ago recognized the tremendous need for a treatment that could provide rapid relief to those suffering from life threatening mood disorders and central neuropathic pain. He is now the Founder and Medical Director of NY Ketamine Infusions, one of the first treatment centers dedicated exclusively to providing ketamine therapy. Dr. Brooks treats patients with mental health conditions, including major depressive disorder, generalized anxiety, post traumatic stress disorder, obsessive compulsive disorder and chronic neuropathic pain. He has treated over 3,000 patients and coordinates infusion treatments with each individual’s referring psychiatrist or therapist. Dr. Brooks completed his training at Harvard’s Brigham and Women’s Hospital and taught at Yale University School of Medicine.

Dr. Darren Cotterell is a geriatric psychiatrist based in Chichester, England. He has obtained multiple psychiatric credentials, including but not limited to an MRCPsych from the United Kingdom in 2006 and a Specialist Certification in Psychiatry form the Royal College of Physicians and Surgeons Canada in 2014. Darren has held the role of Old Age Psychiatrist with Sussex Partnership NHS Foundation Trust since September of 2020. Previously, he held the role of Geriatric Psychiatrist with Island Health of the Vancouver Island Health Authority, which began in June of 2011. Prior to his time on Vancouver Island, Dr. Cotterell held a similar role with Solent NHS Trust in Portsmouth, England from July of 2010. Darren received his Master’s Degree (with Distinction) in Clinical Neuroscience from the University of Roehampton in 2010, subsequent to earning a Bachelor of Medicine, Bachelor of Surgery – MBBS, Medicine from the University of the Witwatersand in 1998.

Dr. Dennis Filips is the principal founder and Chief Medical Officer of Innovative Trauma Care. Dr. Filips, a trauma surgeon, retired from the Canadian Forces after 20 years of service and completing tours in Afghanistan, Bosnia, and the Golan Heights. He completed an Executive MBA program at the Telfer School, University of Ottawa in May 2020. Dennis was an Assistant Adjunct Professor at the National Defense University in Washington DC where he taught Healthcare Industry Studies. He also worked as a general/trauma surgeon in Edmonton and Toronto and as a course director for Advanced Trauma Life Support and Tactical Medicine courses for the military and tactical police units. Dr. Filips completed a trauma fellowship at Sunnybrook & Women’s College Health Sciences in Toronto, Ontario in 2002, his general surgery residency at the University of Toronto in 2001 and medical school at Queen’s University in 1991.

Dr. Quang Henderson is the Founder and Medical Director of MindScape Ketamine & Infusion Therapy, PLLC. He is a licensed Board-Certified Emergency Physician with over 20 years of experience in utilizing ketamine. Dr. Henderson co-founded Neighbors Emergency Centers and previously served on its Board and as Medical Director for several of its facilities. He is passionate about making intravenous ketamine a viable option to those suffering with severe depression, bipolar depression, post traumatic stress disorder, psychiatric disorders and chronic pain. Quang attended Texas A&M University pursuing a degree in Biochemistry. He obtained his Doctor of Medicine degree from The University of Texas Medical Branch. Dr. Henderson completed his Emergency Medicine Residency at UT Houston Health Science Center/Hermann Hospital. He currently also holds the position of Chairperson of Clinical Innovation Council for Ketamine One.

Management Commentary

“It is an honour and a privilege to lead Ketamine One’s Medical Advisory Board and work alongside such an esteemed group of leaders in their respective fields. I am excited to both shape our discussions and learn from them, while ultimately helping to apply the recommendations of our advisors to the Company for the benefit of our patients” said Mark Kimmins, Chief Medical Officer of Ketamine One.

“The establishment of the Medical Advisory Board is an important step in Ketamine One’s strategic evolution and toward its goal of becoming a leader in psychedelic-assisted mental health treatments across the continent. We look forward to continuing to build our leadership capabilities in psychedelics, digital therapeutics and telemedicine,” added Adam Deffett, Interim CEO of Ketamine One.

Options

As consideration for the Medical Advisors’ appointments, the Company has granted each an aggregate of 50,000 stock options to purchase up to 50,000 common shares of the Company, for an aggregate amount of 250,000 stock options to purchase up to 250,000 common shares of the Company, at a price of $1.55 per common share for a period of five years from the date of grant, pursuant to its stock option plan that was approved by shareholders on Feb. 21, 2021. Fifty per cent of the options vest six months from the date of grant, with the remaining fifty per cent of the options vesting 12 months after the date of the grant. Ketamine One has also granted a consultant 100,000 options to purchase 100,000 common shares of the Company at a price of $1.40 per common share, subject to the same other terms as above. The option grants are subject to acceptance by the NEO Exchange.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

"Adam Deffett"
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

FAQ

What is the purpose of Ketamine One's Medical Advisory Board?

The Medical Advisory Board is established to guide the development of Ketamine One's mental health platform and enhance their leadership in psychedelic-assisted treatments.

Who are the key members of Ketamine One's Medical Advisory Board?

The board includes experts such as Dr. Mark Kimmins, Dr. Ravi Bains, Dr. Glen Brooks, and others specializing in psychiatry and innovative mental health treatments.

What stock options were granted to the Medical Advisors of Ketamine One?

Each Medical Advisor was granted 50,000 stock options at a price of $1.55 per share, with a total of 250,000 options allocated for the board.

How does Ketamine One aim to lead in mental health treatments?

Ketamine One aims to become a leader by consolidating medical clinics and focusing on developing innovative psychedelic-assisted therapies.

What is KONEF's strategic evolution in the mental health sector?

KONEF's strategic evolution includes the establishment of a Medical Advisory Board to enhance its leadership capabilities in psychedelics and telemedicine.